Navigation Links
Heiner Dreismann, Ph.D., Former President of Roche Molecular Systems, Joins the HistoRx Board of Directors
Date:10/18/2010

BRANFORD, Conn., Oct. 18 /PRNewswire/ -- HistoRx announced that Heiner Dreismann, Ph.D. has accepted its invitation to join the Board of Directors.  As the former President and CEO of Roche Molecular Systems, Dr. Dreismann is an acknowledged diagnostic industry expert.

Dr. Dreismann was with Hoffmann La Roche for twenty years serving in several roles, including Head of Global Business Development Roche Diagnostics, Head of PCR Business Unit for Europe, President and CEO of Roche Molecular Systems and member of the global Executive Committee of Roche Diagnostics.  HistoRx CEO Rana K. Gupta approached Dr. Dreismann with the opportunity, commenting, "As we reach the commercialization stage of our diagnostics portfolio it's important to add knowledgeable experts from the global distribution companies that have brought new technologies forward to labs around the world.  Heiner's experience with the launch and market development of PCR, and his familiarity with key decision makers across the diagnostics industry make him a valuable addition to the HistoRx Board."

"I am pleased to join the board of directors of HistoRx, a company that has developed a unique and innovative technology to address the key unmet need of the pathology community," Dreismann stated. "HistoRx products have great potential in the United States and overseas markets."

About HistoRx (www.historx.com)

HistoRx, Inc. is a leading developer of tissue-based theranostic solutions to advance individualized patient care. The Company's products and services are based on proprietary AQUA® technology for tissue biomarker analysis. AQUA® software is the only platform capable of precisely measuring protein biomarker concentration with sub-cellular resolution in tissue sections, enabling fully objective, standardized, reproducible, and automated analysis to guide targeted drug development and therapeutic decision making. HistoRx currently helps biopharmaceutical companies advance their product pipelines by generating valuable new insights into the safety and effectiveness of targeted therapeutics in development for cancer and other diseases, and is developing clinical assays based on these insights.  For more information please visit www.historx.com.


'/>"/>
SOURCE HistoRx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. WaferGen Names Gary P. Schroth, Ph.D., as New SVP, Genomics Research and Applications
2. Fibrocell Science, Inc. Names Biotechnology and Genetic Research Expert Stefan Gruenwald, M.D., Ph.D., to Scientific Advisory Board
3. American Humane Association Announces Joy Mench, Ph.D., Joins the Scientific Advisory Committee of the American Humane Certified® Farm Animal Program
4. Melissa Kemp, Ph.D., Wins the Council for Systems Biology in Boston (CSB2) Award Sponsored by Merrimack Pharmaceuticals, Inc.
5. ChemoCentryx President and CEO, Thomas J. Schall, Ph.D., Named Ernst & Young Entrepreneur Of The Year 2010 Award Finalist in Northern California
6. Fate Therapeutics Appoints Tom Novak, Ph.D., as Vice President of Research and Drug Discovery
7. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
8. 5th Annual Szent-Gyorgyi Prize for Progress in Cancer Research Awarded to Peter K. Vogt, Ph.D., The Scripps Research Institute
9. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
10. Amgens Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines
11. Rosalie Dunn, Ph.D., Joins Gwathmey, Inc. as Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... (PRWEB) , ... January 19, ... ... of advanced software solutions for pharmaceutical research and development (R&D), today announced ... in omic data analysis and interpretation for the rapidly evolving field of ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, ... Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious ... agreement for the merger of PharmAthene and Altimmune ... Novartis Venture Fund, HealthCap, Truffle Capital and Redmont ... and diversified immunotherapeutics company with four clinical stage ...
(Date:1/19/2017)... 19, 2017 AquaBounty Technologies, Inc. (AIM: ABTU; ... in aquaculture and a majority-owned subsidiary of Intrexon Corporation ... completed the listing of its common shares on the ... Intrexon. "AquaBounty,s listing on NASDAQ represents an ... exposure to the U.S. markets as we advance plans ...
(Date:1/19/2017)... ... January 18, 2017 , ... ... innovators, engineers, and scientists from around the world, was today awarded the "Best ... program is based entirely on merit and decided upon by a dedicated team ...
Breaking Biology Technology:
(Date:12/19/2016)... , España y TORONTO , 19 de diciembre ... Northern Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, un ... en varios tipos de tumor en 2017, con múltiples sitios previstos ... ... clase con objetivo en el factor inhibidor de leucemia (LIF), una ...
(Date:12/15/2016)... and BADEN-BADEN, Germany , December 15, ... global financial services provider, today announced an agreement with NuData ... biometrics, to join forces. The partnership will enable clients to ... in compliance with local data protection regulation. ... In order to provide ...
(Date:12/15/2016)... 2016  There is much more to innovative access ... engine. Continental will demonstrate the intelligence of today,s solutions ... . Through the combination of the keyless entry and ... elements, the international technology company is opening up new ... "The integration of biometric elements brings our ...
Breaking Biology News(10 mins):